Skip to main content
Premium Trial:

Request an Annual Quote

Reveo Joins Genomics X Prize Race; Aims to Sequence Genome, Proteome, and Epigenome 'for Pennies in Minutes'

NEW YORK  (GenomeWeb News) — Reveo has joined the Archon X Prize race for genome sequencing, the X Prize Foundation said today.
 
Reveo, base in Elmsford, NY, focuses on incubating, developing, and spinning out a variety of technology companies. Its offspring include technologies used in genomics, medical imaging, water desalinization, fuel cells, and optical communications.
 
According to the X Prize Foundation, the device Reveo will use in the Archon X race is the Omni Molecular Recognizer Application, which uses principles from semiconductor electronics and photonics "rather than indirect chemical methods to read the DNA sequence directly."
 
Reveo CEO Sadeg Faris said the biggest challenge his team will confront is fabricating nano-knife edges, which he said has not been done, at least according to published literature.
 
The company said it plans to use arrays of nano-knife-edge probes to "directly and non-destructively" read the human gene sequence.
 
The X Prize said Faris believes Reveo's concept can "accomplish and even surpass" the X Prize's requirements, and can "read an entire human genome, epigenome, and proteome simultaneously in minutes for pennies per genome."
 
Additional information about Reveo’s technology and research can be read here and here.
 
The X Prize launched the Archon X Prize last fall. It is offering $10 million to a team that can make a tool that can sequence 100 human genomes with 99.999-percent accuracy in 10 days for no more than $10,000 per genome.
 
Several industry players have already entered the quest, including VisiGen Biotechnologies, 454 Life Sciences, and the Foundation for Applied Molecular Evolution.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.